949556-47-2

Basic information

• Product Name: 4-(2-fluoro-4-nitrophenoxy)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine
• Synonyms: 4-(2-fluoro-4-nitrophenoxy)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine
• CAS NO: 949556-47-2
• Molecular Weight: 394.362
• Mol File: 949556-47-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(2-fluoro-4-nitrophenoxy)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-fluoro-4-nitrophenoxy)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine(949556-47-2)
• EPA Substance Registry System: 4-(2-fluoro-4-nitrophenoxy)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine(949556-47-2)

Safety Data

• Hazardous Substances Data: 949556-47-2(Hazardous Substances Data)

Upstream product

• 924909-16-0 1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol 
• 369-34-6 3,4-difluoronitrobenzene 

Downstream Products

• 949556-48-3 4-(1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorobenzenamine 
• 949556-53-0 4-(2-fluoro-4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine 

Relevant articles and documents

PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES

Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.

Heterobicyclic pyrazole compounds and methods of use

Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.